id	sid	tid	token	lemma	pos
dpc-1032	1	1	dermatology	dermatology	NOUN
dpc-1032	1	2	:	:	PUNCT
dpc-1032	1	3	practical	practical	ADJ
dpc-1032	1	4	and	and	CCONJ
dpc-1032	1	5	conceptual	conceptual	ADJ
dpc-1032	1	6	letter	letter	NOUN
dpc-1032	2	1	|	|	ADV
dpc-1032	2	2	dermatol	dermatol	ADJ
dpc-1032	2	3	pract	pract	NOUN
dpc-1032	2	4	concept	concept	NOUN
dpc-1032	2	5	2020;10(1):e2020019	2020;10(1):e2020019	NUM
dpc-1032	2	6	1	1	NUM
dpc-1032	2	7	dermatology	dermatology	NOUN
dpc-1032	2	8	practical	practical	ADJ
dpc-1032	2	9	&	&	CCONJ
dpc-1032	2	10	conceptual	conceptual	ADJ
dpc-1032	2	11	introduction	introduction	NOUN
dpc-1032	2	12	tocilizumab	tocilizumab	NOUN
dpc-1032	2	13	(	(	PUNCT
dpc-1032	2	14	tcz	tcz	PROPN
dpc-1032	2	15	)	)	PUNCT
dpc-1032	2	16	is	be	AUX
dpc-1032	2	17	a	a	DET
dpc-1032	2	18	humanized	humanize	VERB
dpc-1032	2	19	monoclonal	monoclonal	NOUN
dpc-1032	2	20	antibody	antibody	NOUN
dpc-1032	2	21	directed	direct	VERB
dpc-1032	2	22	against	against	ADP
dpc-1032	2	23	the	the	DET
dpc-1032	2	24	interleukin	interleukin	NOUN
dpc-1032	2	25	6	6	NUM
dpc-1032	2	26	receptor	receptor	NOUN
dpc-1032	2	27	,	,	PUNCT
dpc-1032	2	28	which	which	PRON
dpc-1032	2	29	has	have	VERB
dpc-1032	2	30	a	a	DET
dpc-1032	2	31	main	main	ADJ
dpc-1032	2	32	use	use	NOUN
dpc-1032	2	33	in	in	ADP
dpc-1032	2	34	the	the	DET
dpc-1032	2	35	treatment	treatment	NOUN
dpc-1032	2	36	of	of	ADP
dpc-1032	2	37	several	several	ADJ
dpc-1032	2	38	rheumatological	rheumatological	ADJ
dpc-1032	2	39	diseases	disease	NOUN
dpc-1032	2	40	but	but	CCONJ
dpc-1032	2	41	also	also	ADV
dpc-1032	2	42	giant	giant	ADJ
dpc-1032	2	43	cell	cell	NOUN
dpc-1032	2	44	arteritis	arteritis	NOUN
dpc-1032	2	45	and	and	CCONJ
dpc-1032	2	46	polymyalgia	polymyalgia	PROPN
dpc-1032	2	47	rheumatica	rheumatica	PROPN
dpc-1032	2	48	.	.	PUNCT
dpc-1032	3	1	despite	despite	SCONJ
dpc-1032	3	2	the	the	DET
dpc-1032	3	3	undoubted	undoubted	ADJ
dpc-1032	3	4	efficacy	efficacy	NOUN
dpc-1032	3	5	of	of	ADP
dpc-1032	3	6	this	this	DET
dpc-1032	3	7	target	target	NOUN
dpc-1032	3	8	therapy	therapy	NOUN
dpc-1032	3	9	,	,	PUNCT
dpc-1032	3	10	immuno	immuno	ADJ
dpc-1032	3	11	-	-	PUNCT
dpc-1032	3	12	mediated	mediate	VERB
dpc-1032	3	13	adverse	adverse	ADJ
dpc-1032	3	14	events	event	NOUN
dpc-1032	3	15	have	have	AUX
dpc-1032	3	16	increasingly	increasingly	ADV
dpc-1032	3	17	been	be	AUX
dpc-1032	3	18	reported	report	VERB
dpc-1032	3	19	,	,	PUNCT
dpc-1032	3	20	including	include	VERB
dpc-1032	3	21	cutaneous	cutaneous	ADJ
dpc-1032	3	22	sarcoidosis	sarcoidosis	NOUN
dpc-1032	3	23	,	,	PUNCT
dpc-1032	3	24	psoriasis	psoriasis	NOUN
dpc-1032	3	25	,	,	PUNCT
dpc-1032	3	26	acute	acute	NOUN
dpc-1032	3	27	generalized	generalize	VERB
dpc-1032	3	28	exanthematous	exanthematous	ADJ
dpc-1032	3	29	pustulosis	pustulosis	NOUN
dpc-1032	3	30	,	,	PUNCT
dpc-1032	3	31	leukocytoclastic	leukocytoclastic	ADJ
dpc-1032	3	32	vasculitis	vasculitis	PROPN
dpc-1032	3	33	,	,	PUNCT
dpc-1032	3	34	drug	drug	NOUN
dpc-1032	3	35	 	 	SPACE
dpc-1032	3	36	reaction	reaction	NOUN
dpc-1032	3	37	with	with	ADP
dpc-1032	3	38	eosinophilia	eosinophilia	PROPN
dpc-1032	3	39	and	and	CCONJ
dpc-1032	3	40	systemic	systemic	ADJ
dpc-1032	3	41	symptoms	symptom	NOUN
dpc-1032	3	42	(	(	PUNCT
dpc-1032	3	43	dress	dress	NOUN
dpc-1032	3	44	)	)	PUNCT
dpc-1032	3	45	syndrome	syndrome	NOUN
dpc-1032	3	46	,	,	PUNCT
dpc-1032	3	47	and	and	CCONJ
dpc-1032	3	48	granuloma	granuloma	ADJ
dpc-1032	3	49	annulare	annulare	NOUN
dpc-1032	3	50	.	.	PUNCT
dpc-1032	4	1	case	case	NOUN
dpc-1032	4	2	presentation	presentation	NOUN
dpc-1032	4	3	a	a	DET
dpc-1032	4	4	75	75	NUM
dpc-1032	4	5	-	-	PUNCT
dpc-1032	4	6	year	year	NOUN
dpc-1032	4	7	-	-	PUNCT
dpc-1032	4	8	old	old	ADJ
dpc-1032	4	9	man	man	NOUN
dpc-1032	4	10	was	be	AUX
dpc-1032	4	11	referred	refer	VERB
dpc-1032	4	12	to	to	ADP
dpc-1032	4	13	our	our	PRON
dpc-1032	4	14	clinic	clinic	NOUN
dpc-1032	4	15	5	5	NUM
dpc-1032	4	16	days	day	NOUN
dpc-1032	4	17	after	after	ADP
dpc-1032	4	18	the	the	DET
dpc-1032	4	19	onset	onset	NOUN
dpc-1032	4	20	of	of	ADP
dpc-1032	4	21	diffuse	diffuse	ADJ
dpc-1032	4	22	multiple	multiple	ADJ
dpc-1032	4	23	painful	painful	ADJ
dpc-1032	4	24	targetoid	targetoid	NOUN
dpc-1032	4	25	plaques	plaque	NOUN
dpc-1032	4	26	asymmetrically	asymmetrically	ADV
dpc-1032	4	27	distributed	distribute	VERB
dpc-1032	4	28	on	on	ADP
dpc-1032	4	29	the	the	DET
dpc-1032	4	30	lower	low	ADJ
dpc-1032	4	31	extremities	extremity	NOUN
dpc-1032	4	32	,	,	PUNCT
dpc-1032	4	33	trunk	trunk	NOUN
dpc-1032	4	34	,	,	PUNCT
dpc-1032	4	35	neck	neck	NOUN
dpc-1032	4	36	,	,	PUNCT
dpc-1032	4	37	and	and	CCONJ
dpc-1032	4	38	nucha	nucha	PROPN
dpc-1032	4	39	.	.	PUNCT
dpc-1032	5	1	the	the	DET
dpc-1032	5	2	lesions	lesion	NOUN
dpc-1032	5	3	were	be	AUX
dpc-1032	5	4	starting	start	VERB
dpc-1032	5	5	to	to	PART
dpc-1032	5	6	coalesce	coalesce	VERB
dpc-1032	5	7	to	to	PART
dpc-1032	5	8	form	form	VERB
dpc-1032	5	9	irregular	irregular	ADJ
dpc-1032	5	10	,	,	PUNCT
dpc-1032	5	11	sharply	sharply	ADV
dpc-1032	5	12	bordered	border	VERB
dpc-1032	5	13	plaques	plaque	NOUN
dpc-1032	5	14	.	.	PUNCT
dpc-1032	6	1	he	he	PRON
dpc-1032	6	2	also	also	ADV
dpc-1032	6	3	presented	present	VERB
dpc-1032	6	4	with	with	ADP
dpc-1032	6	5	a	a	DET
dpc-1032	6	6	marked	mark	VERB
dpc-1032	6	7	periocular	periocular	ADJ
dpc-1032	6	8	swelling	swell	VERB
dpc-1032	6	9	(	(	PUNCT
dpc-1032	6	10	figure	figure	NOUN
dpc-1032	6	11	1	1	NUM
dpc-1032	6	12	,	,	PUNCT
dpc-1032	6	13	a	a	DET
dpc-1032	6	14	-	-	PUNCT
dpc-1032	6	15	d	d	NOUN
dpc-1032	6	16	)	)	PUNCT
dpc-1032	6	17	.	.	PUNCT
dpc-1032	7	1	the	the	DET
dpc-1032	7	2	patient	patient	NOUN
dpc-1032	7	3	had	have	VERB
dpc-1032	7	4	a	a	DET
dpc-1032	7	5	history	history	NOUN
dpc-1032	7	6	of	of	ADP
dpc-1032	7	7	polymyalgia	polymyalgia	PROPN
dpc-1032	7	8	rheumatica	rheumatica	PROPN
dpc-1032	7	9	and	and	CCONJ
dpc-1032	7	10	had	have	AUX
dpc-1032	7	11	been	be	AUX
dpc-1032	7	12	treated	treat	VERB
dpc-1032	7	13	with	with	ADP
dpc-1032	7	14	oral	oral	ADJ
dpc-1032	7	15	steroids	steroid	NOUN
dpc-1032	7	16	for	for	ADP
dpc-1032	7	17	10	10	NUM
dpc-1032	7	18	years	year	NOUN
dpc-1032	7	19	,	,	PUNCT
dpc-1032	7	20	which	which	PRON
dpc-1032	7	21	were	be	AUX
dpc-1032	7	22	then	then	ADV
dpc-1032	7	23	suspended	suspend	VERB
dpc-1032	7	24	because	because	SCONJ
dpc-1032	7	25	of	of	ADP
dpc-1032	7	26	the	the	DET
dpc-1032	7	27	onset	onset	NOUN
dpc-1032	7	28	of	of	ADP
dpc-1032	7	29	severe	severe	ADJ
dpc-1032	7	30	osteoporosis	osteoporosis	NOUN
dpc-1032	7	31	,	,	PUNCT
dpc-1032	7	32	with	with	ADP
dpc-1032	7	33	recurrence	recurrence	NOUN
dpc-1032	7	34	of	of	ADP
dpc-1032	7	35	symptoms	symptom	NOUN
dpc-1032	7	36	.	.	PUNCT
dpc-1032	8	1	hence	hence	ADV
dpc-1032	8	2	,	,	PUNCT
dpc-1032	8	3	subcutaneous	subcutaneous	ADJ
dpc-1032	8	4	tcz	tcz	NOUN
dpc-1032	8	5	was	be	AUX
dpc-1032	8	6	started	start	VERB
dpc-1032	8	7	at	at	ADP
dpc-1032	8	8	the	the	DET
dpc-1032	8	9	dosage	dosage	NOUN
dpc-1032	8	10	of	of	ADP
dpc-1032	8	11	162	162	NUM
dpc-1032	8	12	mg	mg	NUM
dpc-1032	8	13	/	/	SYM
dpc-1032	8	14	week	week	NOUN
dpc-1032	8	15	.	.	PUNCT
dpc-1032	9	1	four	four	NUM
dpc-1032	9	2	days	day	NOUN
dpc-1032	9	3	after	after	ADP
dpc-1032	9	4	the	the	DET
dpc-1032	9	5	first	first	ADJ
dpc-1032	9	6	administration	administration	NOUN
dpc-1032	9	7	of	of	ADP
dpc-1032	9	8	tcz	tcz	PROPN
dpc-1032	9	9	,	,	PUNCT
dpc-1032	9	10	the	the	DET
dpc-1032	9	11	patient	patient	NOUN
dpc-1032	9	12	reported	report	VERB
dpc-1032	9	13	sporadic	sporadic	ADJ
dpc-1032	9	14	painful	painful	ADJ
dpc-1032	9	15	annular	annular	ADJ
dpc-1032	9	16	plaques	plaque	NOUN
dpc-1032	9	17	on	on	ADP
dpc-1032	9	18	his	his	PRON
dpc-1032	9	19	neck	neck	NOUN
dpc-1032	9	20	;	;	PUNCT
dpc-1032	9	21	the	the	DET
dpc-1032	9	22	day	day	NOUN
dpc-1032	9	23	after	after	ADP
dpc-1032	9	24	the	the	DET
dpc-1032	9	25	second	second	ADJ
dpc-1032	9	26	injection	injection	NOUN
dpc-1032	9	27	,	,	PUNCT
dpc-1032	9	28	the	the	DET
dpc-1032	9	29	lesions	lesion	NOUN
dpc-1032	9	30	were	be	AUX
dpc-1032	9	31	spreading	spread	VERB
dpc-1032	9	32	to	to	ADP
dpc-1032	9	33	the	the	DET
dpc-1032	9	34	rest	rest	NOUN
dpc-1032	9	35	of	of	ADP
dpc-1032	9	36	the	the	DET
dpc-1032	9	37	body	body	NOUN
dpc-1032	9	38	.	.	PUNCT
dpc-1032	10	1	moreover	moreover	ADV
dpc-1032	10	2	,	,	PUNCT
dpc-1032	10	3	the	the	DET
dpc-1032	10	4	patient	patient	NOUN
dpc-1032	10	5	reported	report	VERB
dpc-1032	10	6	arthralgias	arthralgia	NOUN
dpc-1032	10	7	,	,	PUNCT
dpc-1032	10	8	general	general	ADJ
dpc-1032	10	9	malaise	malaise	NOUN
dpc-1032	10	10	,	,	PUNCT
dpc-1032	10	11	headache	headache	NOUN
dpc-1032	10	12	,	,	PUNCT
dpc-1032	10	13	and	and	CCONJ
dpc-1032	10	14	fever	fever	NOUN
dpc-1032	10	15	(	(	PUNCT
dpc-1032	10	16	38.3	38.3	NUM
dpc-1032	10	17	°	°	NOUN
dpc-1032	10	18	c	c	NOUN
dpc-1032	10	19	)	)	PUNCT
dpc-1032	10	20	.	.	PUNCT
dpc-1032	11	1	clinical	clinical	ADJ
dpc-1032	11	2	observations	observation	NOUN
dpc-1032	11	3	and	and	CCONJ
dpc-1032	11	4	laboratory	laboratory	NOUN
dpc-1032	11	5	values	value	NOUN
dpc-1032	11	6	were	be	AUX
dpc-1032	11	7	evaluated	evaluate	VERB
dpc-1032	11	8	to	to	PART
dpc-1032	11	9	rule	rule	VERB
dpc-1032	11	10	out	out	ADP
dpc-1032	11	11	other	other	ADJ
dpc-1032	11	12	drug	drug	NOUN
dpc-1032	11	13	-	-	PUNCT
dpc-1032	11	14	induced	induce	VERB
dpc-1032	11	15	conditions	condition	NOUN
dpc-1032	11	16	with	with	ADP
dpc-1032	11	17	cutaneous	cutaneous	ADJ
dpc-1032	11	18	involvement	involvement	NOUN
dpc-1032	11	19	.	.	PUNCT
dpc-1032	12	1	investigations	investigation	NOUN
dpc-1032	12	2	yielded	yield	VERB
dpc-1032	12	3	a	a	DET
dpc-1032	12	4	peripheral	peripheral	ADJ
dpc-1032	12	5	leukocytosis	leukocytosis	NOUN
dpc-1032	12	6	with	with	ADP
dpc-1032	12	7	neutrophilia	neutrophilia	NOUN
dpc-1032	12	8	and	and	CCONJ
dpc-1032	12	9	elevation	elevation	NOUN
dpc-1032	12	10	of	of	ADP
dpc-1032	12	11	erythrocyte	erythrocyte	PROPN
dpc-1032	12	12	sedimentation	sedimentation	NOUN
dpc-1032	12	13	rate	rate	NOUN
dpc-1032	12	14	and	and	CCONJ
dpc-1032	12	15	c	c	NOUN
dpc-1032	12	16	-	-	PUNCT
dpc-1032	12	17	reactive	reactive	ADJ
dpc-1032	12	18	protein	protein	NOUN
dpc-1032	12	19	.	.	PUNCT
dpc-1032	13	1	in	in	ADP
dpc-1032	13	2	erythema	erythema	ADJ
dpc-1032	13	3	multiforme	multiforme	NOUN
dpc-1032	13	4	the	the	DET
dpc-1032	13	5	lesions	lesion	NOUN
dpc-1032	13	6	are	be	AUX
dpc-1032	13	7	itchy	itchy	ADJ
dpc-1032	13	8	and	and	CCONJ
dpc-1032	13	9	typically	typically	ADV
dpc-1032	13	10	start	start	VERB
dpc-1032	13	11	on	on	ADP
dpc-1032	13	12	the	the	DET
dpc-1032	13	13	extremities	extremity	NOUN
dpc-1032	13	14	symmetrically	symmetrically	ADV
dpc-1032	13	15	,	,	PUNCT
dpc-1032	13	16	with	with	ADP
dpc-1032	13	17	centripetal	centripetal	NOUN
dpc-1032	13	18	spreading	spread	VERB
dpc-1032	13	19	[	[	X
dpc-1032	13	20	1	1	NUM
dpc-1032	13	21	]	]	PUNCT
dpc-1032	13	22	.	.	PUNCT
dpc-1032	14	1	a	a	DET
dpc-1032	14	2	key	key	ADJ
dpc-1032	14	3	characteristic	characteristic	NOUN
dpc-1032	14	4	of	of	ADP
dpc-1032	14	5	urticaria	urticaria	NOUN
dpc-1032	14	6	-	-	PUNCT
dpc-1032	14	7	angioedema	angioedema	NOUN
dpc-1032	14	8	is	be	AUX
dpc-1032	14	9	the	the	DET
dpc-1032	14	10	evanescence	evanescence	NOUN
dpc-1032	14	11	of	of	ADP
dpc-1032	14	12	skin	skin	NOUN
dpc-1032	14	13	lesions	lesion	NOUN
dpc-1032	14	14	(	(	PUNCT
dpc-1032	14	15	wheals	wheal	NOUN
dpc-1032	14	16	last	last	VERB
dpc-1032	14	17	less	less	ADJ
dpc-1032	14	18	than	than	ADP
dpc-1032	14	19	24	24	NUM
dpc-1032	14	20	hours	hour	NOUN
dpc-1032	14	21	)	)	PUNCT
dpc-1032	14	22	,	,	PUNCT
dpc-1032	14	23	whereas	whereas	SCONJ
dpc-1032	14	24	our	our	PRON
dpc-1032	14	25	patient	patient	NOUN
dpc-1032	14	26	presented	present	VERB
dpc-1032	14	27	with	with	ADP
dpc-1032	14	28	persistent	persistent	ADJ
dpc-1032	14	29	plaques	plaque	NOUN
dpc-1032	14	30	.	.	PUNCT
dpc-1032	15	1	autoimmune	autoimmune	ADJ
dpc-1032	15	2	screen	screen	NOUN
dpc-1032	15	3	was	be	AUX
dpc-1032	15	4	negative	negative	ADJ
dpc-1032	15	5	and	and	CCONJ
dpc-1032	15	6	sun	sun	NOUN
dpc-1032	15	7	-	-	PUNCT
dpc-1032	15	8	exposed	expose	VERB
dpc-1032	15	9	areas	area	NOUN
dpc-1032	15	10	were	be	AUX
dpc-1032	15	11	spared	spare	VERB
dpc-1032	15	12	,	,	PUNCT
dpc-1032	15	13	so	so	ADV
dpc-1032	15	14	drug	drug	NOUN
dpc-1032	15	15	-	-	PUNCT
dpc-1032	15	16	induced	induce	VERB
dpc-1032	15	17	tocilizumab	tocilizumab	NOUN
dpc-1032	15	18	-	-	PUNCT
dpc-1032	15	19	induced	induce	VERB
dpc-1032	15	20	sweet	sweet	ADJ
dpc-1032	15	21	syndrome	syndrome	NOUN
dpc-1032	15	22	in	in	ADP
dpc-1032	15	23	a	a	DET
dpc-1032	15	24	patient	patient	NOUN
dpc-1032	15	25	with	with	ADP
dpc-1032	15	26	polymyalgia	polymyalgia	PROPN
dpc-1032	15	27	rheumatica	rheumatica	PROPN
dpc-1032	15	28	federica	federica	PROPN
dpc-1032	15	29	filippi,1	filippi,1	PROPN
dpc-1032	15	30	marco	marco	PROPN
dpc-1032	15	31	a.	a.	PROPN
dpc-1032	15	32	chessa,1	chessa,1	PROPN
dpc-1032	15	33	annalisa	annalisa	PROPN
dpc-1032	15	34	patrizi,1	patrizi,1	PROPN
dpc-1032	15	35	carlotta	carlotta	PROPN
dpc-1032	15	36	baraldi,1	baraldi,1	PROPN
dpc-1032	15	37	francesca	francesca	PROPN
dpc-1032	15	38	ferrara,1	ferrara,1	NOUN
dpc-1032	16	1	federico	federico	PROPN
dpc-1032	16	2	bardazzi1	bardazzi1	NOUN
dpc-1032	16	3	1	1	NUM
dpc-1032	16	4	dermatology	dermatology	NOUN
dpc-1032	16	5	,	,	PUNCT
dpc-1032	16	6	department	department	NOUN
dpc-1032	16	7	of	of	ADP
dpc-1032	16	8	experimental	experimental	ADJ
dpc-1032	16	9	,	,	PUNCT
dpc-1032	16	10	diagnostic	diagnostic	ADJ
dpc-1032	16	11	and	and	CCONJ
dpc-1032	16	12	specialty	specialty	NOUN
dpc-1032	16	13	medicine	medicine	NOUN
dpc-1032	16	14	,	,	PUNCT
dpc-1032	16	15	university	university	NOUN
dpc-1032	16	16	of	of	ADP
dpc-1032	16	17	bologna	bologna	PROPN
dpc-1032	16	18	,	,	PUNCT
dpc-1032	16	19	italy	italy	PROPN
dpc-1032	16	20	key	key	ADJ
dpc-1032	16	21	words	word	NOUN
dpc-1032	16	22	:	:	PUNCT
dpc-1032	16	23	tocilizumab	tocilizumab	NOUN
dpc-1032	16	24	,	,	PUNCT
dpc-1032	16	25	tocilizumab	tocilizumab	NOUN
dpc-1032	16	26	-	-	PUNCT
dpc-1032	16	27	induced	induce	VERB
dpc-1032	16	28	sweet	sweet	ADJ
dpc-1032	16	29	syndrome	syndrome	NOUN
dpc-1032	16	30	,	,	PUNCT
dpc-1032	16	31	drug	drug	NOUN
dpc-1032	16	32	-	-	PUNCT
dpc-1032	16	33	induced	induce	VERB
dpc-1032	16	34	sweet	sweet	ADJ
dpc-1032	16	35	syndrome	syndrome	NOUN
dpc-1032	16	36	,	,	PUNCT
dpc-1032	16	37	neutrophilic	neutrophilic	ADJ
dpc-1032	16	38	dermatosis	dermatosis	NOUN
dpc-1032	16	39	citation	citation	NOUN
dpc-1032	16	40	:	:	PUNCT
dpc-1032	16	41	filippi	filippi	PROPN
dpc-1032	16	42	f	f	PROPN
dpc-1032	16	43	,	,	PUNCT
dpc-1032	16	44	chessa	chessa	PROPN
dpc-1032	16	45	ma	ma	PROPN
dpc-1032	16	46	,	,	PUNCT
dpc-1032	16	47	patrizi	patrizi	NOUN
dpc-1032	16	48	a	a	PRON
dpc-1032	16	49	,	,	PUNCT
dpc-1032	16	50	baraldi	baraldi	NOUN
dpc-1032	16	51	c	c	NOUN
dpc-1032	16	52	,	,	PUNCT
dpc-1032	16	53	ferrara	ferrara	NOUN
dpc-1032	16	54	f	f	PROPN
dpc-1032	16	55	,	,	PUNCT
dpc-1032	16	56	bardazzi	bardazzi	PROPN
dpc-1032	16	57	f.	f.	PROPN
dpc-1032	16	58	tocilizumab	tocilizumab	PROPN
dpc-1032	16	59	-	-	PUNCT
dpc-1032	16	60	induced	induce	VERB
dpc-1032	16	61	sweet	sweet	ADJ
dpc-1032	16	62	syndrome	syndrome	NOUN
dpc-1032	16	63	in	in	ADP
dpc-1032	16	64	a	a	DET
dpc-1032	16	65	patient	patient	NOUN
dpc-1032	16	66	with	with	ADP
dpc-1032	16	67	polymyalgia	polymyalgia	PROPN
dpc-1032	16	68	rheumatica	rheumatica	PROPN
dpc-1032	16	69	.	.	PUNCT
dpc-1032	17	1	dermatol	dermatol	NOUN
dpc-1032	17	2	pract	pract	PROPN
dpc-1032	17	3	concept	concept	NOUN
dpc-1032	17	4	.	.	PUNCT
dpc-1032	18	1	2020;10(1):e2020019	2020;10(1):e2020019	NUM
dpc-1032	18	2	.	.	X
dpc-1032	18	3	doi	doi	NOUN
dpc-1032	18	4	:	:	PUNCT
dpc-1032	18	5	https://doi.org/10.5826/dpc.1001a19	https://doi.org/10.5826/dpc.1001a19	ADJ
dpc-1032	18	6	accepted	accept	VERB
dpc-1032	18	7	:	:	PUNCT
dpc-1032	18	8	july	july	PROPN
dpc-1032	18	9	23	23	NUM
dpc-1032	18	10	,	,	PUNCT
dpc-1032	18	11	2019	2019	NUM
dpc-1032	18	12	;	;	PUNCT
dpc-1032	18	13	published	publish	VERB
dpc-1032	18	14	:	:	PUNCT
dpc-1032	18	15	december	december	PROPN
dpc-1032	18	16	31	31	NUM
dpc-1032	18	17	,	,	PUNCT
dpc-1032	18	18	2019	2019	NUM
dpc-1032	18	19	copyright	copyright	NOUN
dpc-1032	18	20	:	:	PUNCT
dpc-1032	19	1	©	©	PROPN
dpc-1032	19	2	2019	2019	NUM
dpc-1032	19	3	filippi	filippi	PROPN
dpc-1032	19	4	et	et	PROPN
dpc-1032	19	5	al	al	PROPN
dpc-1032	19	6	.	.	PUNCT
dpc-1032	20	1	this	this	PRON
dpc-1032	20	2	is	be	AUX
dpc-1032	20	3	an	an	DET
dpc-1032	20	4	open	open	ADJ
dpc-1032	20	5	-	-	PUNCT
dpc-1032	20	6	access	access	NOUN
dpc-1032	20	7	article	article	NOUN
dpc-1032	20	8	distributed	distribute	VERB
dpc-1032	20	9	under	under	ADP
dpc-1032	20	10	the	the	DET
dpc-1032	20	11	terms	term	NOUN
dpc-1032	20	12	of	of	ADP
dpc-1032	20	13	the	the	DET
dpc-1032	20	14	creative	creative	ADJ
dpc-1032	20	15	commons	common	NOUN
dpc-1032	20	16	attribution	attribution	NOUN
dpc-1032	20	17	license	license	NOUN
dpc-1032	20	18	,	,	PUNCT
dpc-1032	20	19	which	which	PRON
dpc-1032	20	20	permits	permit	VERB
dpc-1032	20	21	unrestricted	unrestricted	ADJ
dpc-1032	20	22	use	use	NOUN
dpc-1032	20	23	,	,	PUNCT
dpc-1032	20	24	distribution	distribution	NOUN
dpc-1032	20	25	,	,	PUNCT
dpc-1032	20	26	and	and	CCONJ
dpc-1032	20	27	reproduction	reproduction	NOUN
dpc-1032	20	28	in	in	ADP
dpc-1032	20	29	any	any	DET
dpc-1032	20	30	medium	medium	NOUN
dpc-1032	20	31	,	,	PUNCT
dpc-1032	20	32	provided	provide	VERB
dpc-1032	20	33	the	the	DET
dpc-1032	20	34	original	original	ADJ
dpc-1032	20	35	author	author	NOUN
dpc-1032	20	36	and	and	CCONJ
dpc-1032	20	37	source	source	NOUN
dpc-1032	20	38	are	be	AUX
dpc-1032	20	39	credited	credit	VERB
dpc-1032	20	40	.	.	PUNCT
dpc-1032	21	1	funding	funding	NOUN
dpc-1032	21	2	:	:	PUNCT
dpc-1032	21	3	none	none	NOUN
dpc-1032	21	4	.	.	PUNCT
dpc-1032	22	1	competing	compete	VERB
dpc-1032	22	2	interests	interest	NOUN
dpc-1032	22	3	:	:	PUNCT
dpc-1032	22	4	the	the	DET
dpc-1032	22	5	authors	author	NOUN
dpc-1032	22	6	have	have	VERB
dpc-1032	22	7	no	no	DET
dpc-1032	22	8	conflicts	conflict	NOUN
dpc-1032	22	9	of	of	ADP
dpc-1032	22	10	interest	interest	NOUN
dpc-1032	22	11	to	to	PART
dpc-1032	22	12	disclose	disclose	VERB
dpc-1032	22	13	.	.	PUNCT
dpc-1032	23	1	authorship	authorship	NOUN
dpc-1032	23	2	:	:	PUNCT
dpc-1032	23	3	f.f	f.f	PROPN
dpc-1032	23	4	.	.	PROPN
dpc-1032	23	5	,	,	PUNCT
dpc-1032	23	6	m.a.c	m.a.c	ADV
dpc-1032	23	7	.	.	PUNCT
dpc-1032	23	8	,	,	PUNCT
dpc-1032	23	9	and	and	CCONJ
dpc-1032	23	10	f.b	f.b	PROPN
dpc-1032	23	11	.	.	PROPN
dpc-1032	23	12	contributed	contribute	VERB
dpc-1032	23	13	equally	equally	ADV
dpc-1032	23	14	to	to	ADP
dpc-1032	23	15	this	this	DET
dpc-1032	23	16	work	work	NOUN
dpc-1032	23	17	.	.	PUNCT
dpc-1032	24	1	all	all	DET
dpc-1032	24	2	authors	author	NOUN
dpc-1032	24	3	have	have	AUX
dpc-1032	24	4	contributed	contribute	VERB
dpc-1032	24	5	significantly	significantly	ADV
dpc-1032	24	6	to	to	ADP
dpc-1032	24	7	this	this	DET
dpc-1032	24	8	publication	publication	NOUN
dpc-1032	24	9	.	.	PUNCT
dpc-1032	25	1	corresponding	correspond	VERB
dpc-1032	25	2	author	author	NOUN
dpc-1032	25	3	:	:	PUNCT
dpc-1032	25	4	marco	marco	PROPN
dpc-1032	25	5	a.	a.	PROPN
dpc-1032	25	6	chessa	chessa	PROPN
dpc-1032	25	7	,	,	PUNCT
dpc-1032	25	8	md	md	PROPN
dpc-1032	25	9	,	,	PUNCT
dpc-1032	25	10	dermatology	dermatology	NOUN
dpc-1032	25	11	,	,	PUNCT
dpc-1032	25	12	department	department	NOUN
dpc-1032	25	13	of	of	ADP
dpc-1032	25	14	experimental	experimental	ADJ
dpc-1032	25	15	,	,	PUNCT
dpc-1032	25	16	diagnostic	diagnostic	ADJ
dpc-1032	25	17	and	and	CCONJ
dpc-1032	25	18	specialty	specialty	NOUN
dpc-1032	25	19	medicine	medicine	NOUN
dpc-1032	25	20	,	,	PUNCT
dpc-1032	25	21	university	university	NOUN
dpc-1032	25	22	of	of	ADP
dpc-1032	25	23	bologna	bologna	NOUN
dpc-1032	25	24	,	,	PUNCT
dpc-1032	25	25	via	via	ADP
dpc-1032	25	26	massarenti	massarenti	PROPN
dpc-1032	25	27	,	,	PUNCT
dpc-1032	25	28	1	1	NUM
dpc-1032	25	29	-	-	SYM
dpc-1032	25	30	40138	40138	NUM
dpc-1032	25	31	bologna	bologna	PROPN
dpc-1032	25	32	,	,	PUNCT
dpc-1032	25	33	italy	italy	PROPN
dpc-1032	25	34	.	.	PUNCT
dpc-1032	26	1	email	email	NOUN
dpc-1032	26	2	:	:	PUNCT
dpc-1032	26	3	marcoadriano.chessa@gmail.com	marcoadriano.chessa@gmail.com	X
dpc-1032	26	4	mailto:marcoadriano.chessa@gmail.com	mailto:marcoadriano.chessa@gmail.com	NOUN
dpc-1032	26	5	2	2	NUM
dpc-1032	26	6	letter	letter	NOUN
dpc-1032	26	7	|	|	ADV
dpc-1032	26	8	dermatol	dermatol	ADJ
dpc-1032	26	9	pract	pract	NOUN
dpc-1032	26	10	concept	concept	NOUN
dpc-1032	26	11	2020;10(1):e2020019	2020;10(1):e2020019	NUM
dpc-1032	26	12	(	(	PUNCT
dpc-1032	26	13	0.05	0.05	NUM
dpc-1032	26	14	%	%	NOUN
dpc-1032	26	15	clobetasol	clobetasol	NOUN
dpc-1032	26	16	propionate	propionate	NOUN
dpc-1032	26	17	cream	cream	NOUN
dpc-1032	26	18	)	)	PUNCT
dpc-1032	26	19	once	once	ADV
dpc-1032	26	20	daily	daily	ADV
dpc-1032	26	21	were	be	AUX
dpc-1032	26	22	prescribed	prescribe	VERB
dpc-1032	26	23	.	.	PUNCT
dpc-1032	27	1	the	the	DET
dpc-1032	27	2	systemic	systemic	ADJ
dpc-1032	27	3	steroid	steroid	NOUN
dpc-1032	27	4	was	be	AUX
dpc-1032	27	5	tapered	taper	VERB
dpc-1032	27	6	to	to	ADP
dpc-1032	27	7	10	10	NUM
dpc-1032	27	8	mg	mg	NUM
dpc-1032	27	9	/	/	SYM
dpc-1032	27	10	day	day	NOUN
dpc-1032	27	11	within	within	ADP
dpc-1032	27	12	consequently	consequently	ADV
dpc-1032	27	13	,	,	PUNCT
dpc-1032	27	14	tcz	tcz	PROPN
dpc-1032	27	15	was	be	AUX
dpc-1032	27	16	discontinued	discontinue	VERB
dpc-1032	27	17	and	and	CCONJ
dpc-1032	27	18	oral	oral	ADJ
dpc-1032	27	19	prednisone	prednisone	NOUN
dpc-1032	27	20	at	at	ADP
dpc-1032	27	21	a	a	DET
dpc-1032	27	22	dosage	dosage	NOUN
dpc-1032	27	23	of	of	ADP
dpc-1032	27	24	0.6	0.6	NUM
dpc-1032	27	25	mg	mg	PROPN
dpc-1032	27	26	/	/	SYM
dpc-1032	27	27	kg	kg	NOUN
dpc-1032	27	28	/	/	SYM
dpc-1032	27	29	day	day	NOUN
dpc-1032	27	30	and	and	CCONJ
dpc-1032	27	31	a	a	DET
dpc-1032	27	32	topical	topical	ADJ
dpc-1032	27	33	steroid	steroid	NOUN
dpc-1032	27	34	subacute	subacute	NOUN
dpc-1032	27	35	cutaneous	cutaneous	ADJ
dpc-1032	27	36	lupus	lupus	PROPN
dpc-1032	27	37	erythematosus	erythematosus	NOUN
dpc-1032	27	38	(	(	PUNCT
dpc-1032	27	39	antinuclear	antinuclear	ADJ
dpc-1032	27	40	antibody	antibody	VERB
dpc-1032	27	41	positive	positive	ADJ
dpc-1032	27	42	in	in	ADP
dpc-1032	27	43	60%-80	60%-80	NUM
dpc-1032	27	44	%	%	NOUN
dpc-1032	27	45	of	of	ADP
dpc-1032	27	46	cases	case	NOUN
dpc-1032	27	47	)	)	PUNCT
dpc-1032	27	48	was	be	AUX
dpc-1032	27	49	excluded	exclude	VERB
dpc-1032	27	50	.	.	PUNCT
dpc-1032	28	1	finally	finally	ADV
dpc-1032	28	2	,	,	PUNCT
dpc-1032	28	3	wells	wells	PROPN
dpc-1032	28	4	syndrome	syndrome	PROPN
dpc-1032	28	5	is	be	AUX
dpc-1032	28	6	characterized	characterize	VERB
dpc-1032	28	7	by	by	ADP
dpc-1032	28	8	itchy	itchy	ADJ
dpc-1032	28	9	and	and	CCONJ
dpc-1032	28	10	indurated	indurate	VERB
dpc-1032	28	11	plaques	plaque	NOUN
dpc-1032	28	12	with	with	ADP
dpc-1032	28	13	erythema	erythema	ADJ
dpc-1032	28	14	and	and	CCONJ
dpc-1032	28	15	edema	edema	NOUN
dpc-1032	28	16	,	,	PUNCT
dpc-1032	28	17	and	and	CCONJ
dpc-1032	28	18	systemic	systemic	ADJ
dpc-1032	28	19	symptoms	symptom	NOUN
dpc-1032	28	20	may	may	AUX
dpc-1032	28	21	be	be	AUX
dpc-1032	28	22	present	present	ADJ
dpc-1032	28	23	,	,	PUNCT
dpc-1032	28	24	so	so	CCONJ
dpc-1032	28	25	histopathology	histopathology	NOUN
dpc-1032	28	26	is	be	AUX
dpc-1032	28	27	mandatory	mandatory	ADJ
dpc-1032	28	28	for	for	ADP
dpc-1032	28	29	differential	differential	ADJ
dpc-1032	28	30	diagnosis	diagnosis	NOUN
dpc-1032	28	31	.	.	PUNCT
dpc-1032	29	1	histopathological	histopathological	ADJ
dpc-1032	29	2	examination	examination	NOUN
dpc-1032	29	3	showed	show	VERB
dpc-1032	29	4	a	a	DET
dpc-1032	29	5	dense	dense	ADJ
dpc-1032	29	6	perivascular	perivascular	ADJ
dpc-1032	29	7	infiltrate	infiltrate	NOUN
dpc-1032	29	8	composed	compose	VERB
dpc-1032	29	9	largely	largely	ADV
dpc-1032	29	10	of	of	ADP
dpc-1032	29	11	neutrophils	neutrophil	NOUN
dpc-1032	29	12	throughout	throughout	ADP
dpc-1032	29	13	the	the	DET
dpc-1032	29	14	papillary	papillary	ADJ
dpc-1032	29	15	dermis	dermis	NOUN
dpc-1032	29	16	(	(	PUNCT
dpc-1032	29	17	figure	figure	NOUN
dpc-1032	29	18	1	1	NUM
dpc-1032	29	19	,	,	PUNCT
dpc-1032	29	20	e	e	NOUN
dpc-1032	29	21	and	and	CCONJ
dpc-1032	29	22	f	f	PROPN
dpc-1032	29	23	)	)	PUNCT
dpc-1032	29	24	.	.	PUNCT
dpc-1032	30	1	sweet	sweet	ADJ
dpc-1032	30	2	syndrome	syndrome	NOUN
dpc-1032	30	3	is	be	AUX
dpc-1032	30	4	the	the	DET
dpc-1032	30	5	most	most	ADV
dpc-1032	30	6	representative	representative	ADJ
dpc-1032	30	7	entity	entity	NOUN
dpc-1032	30	8	of	of	ADP
dpc-1032	30	9	febrile	febrile	NOUN
dpc-1032	30	10	neutrophilic	neutrophilic	PROPN
dpc-1032	30	11	dermatoses	dermatosis	NOUN
dpc-1032	30	12	.	.	PUNCT
dpc-1032	31	1	it	it	PRON
dpc-1032	31	2	can	can	AUX
dpc-1032	31	3	present	present	VERB
dpc-1032	31	4	as	as	ADP
dpc-1032	31	5	1	1	NUM
dpc-1032	31	6	of	of	ADP
dpc-1032	31	7	3	3	NUM
dpc-1032	31	8	clinical	clinical	ADJ
dpc-1032	31	9	types	type	NOUN
dpc-1032	31	10	:	:	PUNCT
dpc-1032	31	11	classic	classic	ADJ
dpc-1032	31	12	or	or	CCONJ
dpc-1032	31	13	idiopathic	idiopathic	ADJ
dpc-1032	31	14	,	,	PUNCT
dpc-1032	31	15	malignancy	malignancy	NOUN
dpc-1032	31	16	-	-	PUNCT
dpc-1032	31	17	associated	associate	VERB
dpc-1032	31	18	,	,	PUNCT
dpc-1032	31	19	or	or	CCONJ
dpc-1032	31	20	drug	drug	NOUN
dpc-1032	31	21	-	-	PUNCT
dpc-1032	31	22	induced	induce	VERB
dpc-1032	31	23	.	.	PUNCT
dpc-1032	32	1	in	in	ADP
dpc-1032	32	2	drug	drug	NOUN
dpc-1032	32	3	-	-	PUNCT
dpc-1032	32	4	induced	induce	VERB
dpc-1032	32	5	sweet	sweet	ADJ
dpc-1032	32	6	syndrome	syndrome	NOUN
dpc-1032	32	7	,	,	PUNCT
dpc-1032	32	8	all	all	PRON
dpc-1032	32	9	of	of	ADP
dpc-1032	32	10	the	the	DET
dpc-1032	32	11	following	follow	VERB
dpc-1032	32	12	criteria	criterion	NOUN
dpc-1032	32	13	should	should	AUX
dpc-1032	32	14	be	be	AUX
dpc-1032	32	15	present	present	ADJ
dpc-1032	32	16	to	to	PART
dpc-1032	32	17	achieve	achieve	VERB
dpc-1032	32	18	the	the	DET
dpc-1032	32	19	diagnosis	diagnosis	NOUN
dpc-1032	32	20	:	:	PUNCT
dpc-1032	32	21	(	(	PUNCT
dpc-1032	32	22	1	1	X
dpc-1032	32	23	)	)	PUNCT
dpc-1032	32	24	abrupt	abrupt	ADJ
dpc-1032	32	25	onset	onset	NOUN
dpc-1032	32	26	of	of	ADP
dpc-1032	32	27	painful	painful	ADJ
dpc-1032	32	28	erythematous	erythematous	ADJ
dpc-1032	32	29	plaques	plaque	NOUN
dpc-1032	32	30	or	or	CCONJ
dpc-1032	32	31	nodules	nodule	NOUN
dpc-1032	32	32	;	;	PUNCT
dpc-1032	32	33	(	(	PUNCT
dpc-1032	32	34	2	2	X
dpc-1032	32	35	)	)	PUNCT
dpc-1032	32	36	histopathological	histopathological	ADJ
dpc-1032	32	37	findings	finding	NOUN
dpc-1032	32	38	of	of	ADP
dpc-1032	32	39	dense	dense	ADJ
dpc-1032	32	40	neutrophilic	neutrophilic	ADJ
dpc-1032	32	41	infiltrate	infiltrate	NOUN
dpc-1032	32	42	without	without	ADP
dpc-1032	32	43	evidence	evidence	NOUN
dpc-1032	32	44	of	of	ADP
dpc-1032	32	45	leukocytoclastic	leukocytoclastic	ADJ
dpc-1032	32	46	vasculitis	vasculitis	NOUN
dpc-1032	32	47	;	;	PUNCT
dpc-1032	32	48	(	(	PUNCT
dpc-1032	32	49	3	3	X
dpc-1032	32	50	)	)	PUNCT
dpc-1032	32	51	fever	fever	NOUN
dpc-1032	32	52	>	>	X
dpc-1032	32	53	38	38	NUM
dpc-1032	32	54	°	°	SYM
dpc-1032	32	55	c	c	NOUN
dpc-1032	32	56	;	;	PUNCT
dpc-1032	32	57	(	(	PUNCT
dpc-1032	32	58	4	4	X
dpc-1032	32	59	)	)	PUNCT
dpc-1032	32	60	temporal	temporal	ADJ
dpc-1032	32	61	relation	relation	NOUN
dpc-1032	32	62	between	between	ADP
dpc-1032	32	63	use	use	NOUN
dpc-1032	32	64	of	of	ADP
dpc-1032	32	65	medication	medication	NOUN
dpc-1032	32	66	and	and	CCONJ
dpc-1032	32	67	clinical	clinical	ADJ
dpc-1032	32	68	presentation	presentation	NOUN
dpc-1032	32	69	or	or	CCONJ
dpc-1032	32	70	relapse	relapse	VERB
dpc-1032	32	71	with	with	ADP
dpc-1032	32	72	readministration	readministration	NOUN
dpc-1032	32	73	;	;	PUNCT
dpc-1032	32	74	and	and	CCONJ
dpc-1032	32	75	(	(	PUNCT
dpc-1032	32	76	5	5	X
dpc-1032	32	77	)	)	PUNCT
dpc-1032	32	78	disappearance	disappearance	NOUN
dpc-1032	32	79	of	of	ADP
dpc-1032	32	80	lesions	lesion	NOUN
dpc-1032	32	81	after	after	ADP
dpc-1032	32	82	drug	drug	NOUN
dpc-1032	32	83	discontinuation	discontinuation	NOUN
dpc-1032	32	84	or	or	CCONJ
dpc-1032	32	85	treatment	treatment	NOUN
dpc-1032	32	86	with	with	ADP
dpc-1032	32	87	systemic	systemic	ADJ
dpc-1032	32	88	corticosteroids	corticosteroid	NOUN
dpc-1032	32	89	[	[	X
dpc-1032	32	90	2	2	NUM
dpc-1032	32	91	]	]	PUNCT
dpc-1032	32	92	.	.	PUNCT
dpc-1032	33	1	our	our	PRON
dpc-1032	33	2	case	case	NOUN
dpc-1032	33	3	fulfilled	fulfil	VERB
dpc-1032	33	4	all	all	PRON
dpc-1032	33	5	of	of	ADP
dpc-1032	33	6	these	these	DET
dpc-1032	33	7	criteria	criterion	NOUN
dpc-1032	33	8	and	and	CCONJ
dpc-1032	33	9	thus	thus	ADV
dpc-1032	33	10	the	the	DET
dpc-1032	33	11	diagnosis	diagnosis	NOUN
dpc-1032	33	12	of	of	ADP
dpc-1032	33	13	tcz	tcz	NOUN
dpc-1032	33	14	-	-	PUNCT
dpc-1032	33	15	induced	induce	VERB
dpc-1032	33	16	sweet	sweet	ADJ
dpc-1032	33	17	syndrome	syndrome	NOUN
dpc-1032	33	18	was	be	AUX
dpc-1032	33	19	made	make	VERB
dpc-1032	33	20	.	.	PUNCT
dpc-1032	34	1	figure	figure	VERB
dpc-1032	34	2	1	1	NUM
dpc-1032	34	3	.	.	PUNCT
dpc-1032	35	1	clinical	clinical	ADJ
dpc-1032	35	2	and	and	CCONJ
dpc-1032	35	3	histopathological	histopathological	ADJ
dpc-1032	35	4	findings	finding	NOUN
dpc-1032	35	5	.	.	PUNCT
dpc-1032	36	1	(	(	PUNCT
dpc-1032	36	2	a	a	DET
dpc-1032	36	3	-	-	PUNCT
dpc-1032	36	4	d	d	NOUN
dpc-1032	36	5	)	)	PUNCT
dpc-1032	36	6	multiple	multiple	ADJ
dpc-1032	36	7	painful	painful	ADJ
dpc-1032	36	8	targetoid	targetoid	ADJ
dpc-1032	36	9	plaques	plaque	NOUN
dpc-1032	36	10	characterized	characterize	VERB
dpc-1032	36	11	by	by	ADP
dpc-1032	36	12	irregular	irregular	ADJ
dpc-1032	36	13	sharp	sharp	ADJ
dpc-1032	36	14	border	border	NOUN
dpc-1032	36	15	,	,	PUNCT
dpc-1032	36	16	central	central	ADJ
dpc-1032	36	17	desquamative	desquamative	ADJ
dpc-1032	36	18	rim	rim	NOUN
dpc-1032	36	19	in	in	ADP
dpc-1032	36	20	some	some	DET
dpc-1032	36	21	lesions	lesion	NOUN
dpc-1032	36	22	and	and	CCONJ
dpc-1032	36	23	asymmetrically	asymmetrically	ADV
dpc-1032	36	24	distributed	distribute	VERB
dpc-1032	36	25	on	on	ADP
dpc-1032	36	26	lower	low	ADJ
dpc-1032	36	27	extremities	extremity	NOUN
dpc-1032	36	28	,	,	PUNCT
dpc-1032	36	29	trunk	trunk	NOUN
dpc-1032	36	30	,	,	PUNCT
dpc-1032	36	31	neck	neck	NOUN
dpc-1032	36	32	,	,	PUNCT
dpc-1032	36	33	and	and	CCONJ
dpc-1032	36	34	nucha	nucha	PROPN
dpc-1032	36	35	.	.	PUNCT
dpc-1032	37	1	periocular	periocular	ADJ
dpc-1032	37	2	swelling	swelling	NOUN
dpc-1032	37	3	,	,	PUNCT
dpc-1032	37	4	left	leave	VERB
dpc-1032	37	5	side	side	NOUN
dpc-1032	37	6	worse	bad	ADJ
dpc-1032	37	7	than	than	ADP
dpc-1032	37	8	right	right	ADJ
dpc-1032	37	9	.	.	PUNCT
dpc-1032	38	1	(	(	PUNCT
dpc-1032	38	2	e	e	X
dpc-1032	38	3	)	)	PUNCT
dpc-1032	38	4	dense	dense	ADJ
dpc-1032	38	5	infiltrate	infiltrate	NOUN
dpc-1032	38	6	composed	compose	VERB
dpc-1032	38	7	largely	largely	ADV
dpc-1032	38	8	of	of	ADP
dpc-1032	38	9	neutrophils	neutrophil	NOUN
dpc-1032	38	10	in	in	ADP
dpc-1032	38	11	the	the	DET
dpc-1032	38	12	upper	upper	ADJ
dpc-1032	38	13	dermis	dermis	NOUN
dpc-1032	38	14	(	(	PUNCT
dpc-1032	38	15	h&e	h&e	PROPN
dpc-1032	38	16	,	,	PUNCT
dpc-1032	38	17	×4	×4	NOUN
dpc-1032	38	18	)	)	PUNCT
dpc-1032	38	19	.	.	PUNCT
dpc-1032	39	1	(	(	PUNCT
dpc-1032	39	2	f	f	X
dpc-1032	39	3	)	)	PUNCT
dpc-1032	39	4	higher	high	ADJ
dpc-1032	39	5	magnification	magnification	NOUN
dpc-1032	39	6	of	of	ADP
dpc-1032	39	7	the	the	DET
dpc-1032	39	8	neutrophilic	neutrophilic	ADJ
dpc-1032	39	9	infiltrate	infiltrate	NOUN
dpc-1032	39	10	with	with	ADP
dpc-1032	39	11	some	some	DET
dpc-1032	39	12	nuclear	nuclear	ADJ
dpc-1032	39	13	fragmentation	fragmentation	NOUN
dpc-1032	39	14	;	;	PUNCT
dpc-1032	39	15	vasodilation	vasodilation	NOUN
dpc-1032	39	16	and	and	CCONJ
dpc-1032	39	17	swelling	swelling	NOUN
dpc-1032	39	18	of	of	ADP
dpc-1032	39	19	endothelium	endothelium	NOUN
dpc-1032	39	20	with	with	ADP
dpc-1032	39	21	moderate	moderate	ADJ
dpc-1032	39	22	extravasation	extravasation	NOUN
dpc-1032	39	23	of	of	ADP
dpc-1032	39	24	erythrocytes	erythrocytes	PROPN
dpc-1032	39	25	and	and	CCONJ
dpc-1032	39	26	prominent	prominent	ADJ
dpc-1032	39	27	edema	edema	NOUN
dpc-1032	39	28	were	be	AUX
dpc-1032	39	29	also	also	ADV
dpc-1032	39	30	present	present	ADJ
dpc-1032	39	31	(	(	PUNCT
dpc-1032	39	32	h&e	h&e	PROPN
dpc-1032	39	33	,	,	PUNCT
dpc-1032	39	34	×10	×10	PROPN
dpc-1032	39	35	)	)	PUNCT
dpc-1032	39	36	.	.	PUNCT
dpc-1032	40	1	(	(	PUNCT
dpc-1032	40	2	g	g	NOUN
dpc-1032	40	3	,	,	PUNCT
dpc-1032	40	4	h	h	NOUN
dpc-1032	40	5	)	)	PUNCT
dpc-1032	40	6	clinical	clinical	ADJ
dpc-1032	40	7	remission	remission	NOUN
dpc-1032	40	8	within	within	ADP
dpc-1032	40	9	3	3	NUM
dpc-1032	40	10	months	month	NOUN
dpc-1032	40	11	,	,	PUNCT
dpc-1032	40	12	after	after	ADP
dpc-1032	40	13	tocilizumab	tocilizumab	NOUN
dpc-1032	40	14	interruption	interruption	NOUN
dpc-1032	40	15	and	and	CCONJ
dpc-1032	40	16	systemic	systemic	ADJ
dpc-1032	40	17	and	and	CCONJ
dpc-1032	40	18	topical	topical	ADJ
dpc-1032	40	19	steroid	steroid	PROPN
dpc-1032	40	20	administration	administration	NOUN
dpc-1032	40	21	.	.	PUNCT
dpc-1032	41	1	letter	letter	NOUN
dpc-1032	42	1	|	|	ADV
dpc-1032	42	2	dermatol	dermatol	ADJ
dpc-1032	42	3	pract	pract	NOUN
dpc-1032	42	4	concept	concept	NOUN
dpc-1032	42	5	2020;10(1):e2020019	2020;10(1):e2020019	NUM
dpc-1032	42	6	3	3	NUM
dpc-1032	42	7	duced	duce	VERB
dpc-1032	42	8	subacute	subacute	NOUN
dpc-1032	42	9	cutaneous	cutaneous	ADJ
dpc-1032	42	10	lupus	lupus	NOUN
dpc-1032	42	11	with	with	ADP
dpc-1032	42	12	erythema	erythema	ADJ
dpc-1032	42	13	multiforme	multiforme	NOUN
dpc-1032	42	14	-	-	PUNCT
dpc-1032	42	15	like	like	ADJ
dpc-1032	42	16	lesions	lesion	NOUN
dpc-1032	42	17	:	:	PUNCT
dpc-1032	42	18	the	the	DET
dpc-1032	42	19	enigma	enigma	NOUN
dpc-1032	42	20	of	of	ADP
dpc-1032	42	21	the	the	DET
dpc-1032	42	22	rowell	rowell	PROPN
dpc-1032	42	23	syndrome	syndrome	PROPN
dpc-1032	42	24	.	.	PUNCT
dpc-1032	43	1	j	j	PROPN
dpc-1032	43	2	dtsch	dtsch	PROPN
dpc-1032	43	3	dermatol	dermatol	NOUN
dpc-1032	43	4	ges	ge	NOUN
dpc-1032	43	5	.	.	PROPN
dpc-1032	43	6	2014;12(11):1039	2014;12(11):1039	NOUN
dpc-1032	43	7	-	-	NOUN
dpc-1032	43	8	1042	1042	NUM
dpc-1032	43	9	.	.	PUNCT
dpc-1032	44	1	2	2	X
dpc-1032	44	2	.	.	X
dpc-1032	44	3	walker	walker	PROPN
dpc-1032	44	4	dc	dc	PROPN
dpc-1032	44	5	,	,	PUNCT
dpc-1032	44	6	cohen	cohen	PROPN
dpc-1032	44	7	pr	pr	PROPN
dpc-1032	44	8	.	.	PUNCT
dpc-1032	44	9	trimethoprim	trimethoprim	ADJ
dpc-1032	44	10	-	-	PUNCT
dpc-1032	44	11	sulfamethoxazole	sulfamethoxazole	NOUN
dpc-1032	44	12	-	-	PUNCT
dpc-1032	44	13	associated	associate	VERB
dpc-1032	44	14	acute	acute	ADJ
dpc-1032	44	15	febrile	febrile	NOUN
dpc-1032	44	16	neutrophilic	neutrophilic	ADJ
dpc-1032	44	17	dermatosis	dermatosis	NOUN
dpc-1032	44	18	:	:	PUNCT
dpc-1032	44	19	case	case	NOUN
dpc-1032	44	20	report	report	NOUN
dpc-1032	44	21	and	and	CCONJ
dpc-1032	44	22	review	review	NOUN
dpc-1032	44	23	of	of	ADP
dpc-1032	44	24	drug	drug	NOUN
dpc-1032	44	25	-	-	PUNCT
dpc-1032	44	26	induced	induce	VERB
dpc-1032	44	27	sweet	sweet	ADJ
dpc-1032	44	28	’s	’s	PART
dpc-1032	44	29	syndrome	syndrome	NOUN
dpc-1032	44	30	.	.	PUNCT
dpc-1032	45	1	j	j	PROPN
dpc-1032	45	2	am	be	AUX
dpc-1032	45	3	acad	acad	ADJ
dpc-1032	45	4	dermatol	dermatol	NOUN
dpc-1032	45	5	.	.	PUNCT
dpc-1032	46	1	1996;34(5	1996;34(5	PROPN
dpc-1032	46	2	pt	pt	PROPN
dpc-1032	46	3	2):918	2):918	NUM
dpc-1032	46	4	-	-	SYM
dpc-1032	46	5	923	923	NUM
dpc-1032	46	6	.	.	PUNCT
dpc-1032	47	1	conclusions	conclusion	NOUN
dpc-1032	47	2	in	in	ADP
dpc-1032	47	3	conclusion	conclusion	NOUN
dpc-1032	47	4	,	,	PUNCT
dpc-1032	47	5	clinicians	clinician	NOUN
dpc-1032	47	6	should	should	AUX
dpc-1032	47	7	be	be	AUX
dpc-1032	47	8	aware	aware	ADJ
dpc-1032	47	9	of	of	ADP
dpc-1032	47	10	this	this	DET
dpc-1032	47	11	possible	possible	ADJ
dpc-1032	47	12	reaction	reaction	NOUN
dpc-1032	47	13	even	even	ADV
dpc-1032	47	14	though	though	SCONJ
dpc-1032	47	15	the	the	DET
dpc-1032	47	16	causality	causality	NOUN
dpc-1032	47	17	has	have	AUX
dpc-1032	47	18	not	not	PART
dpc-1032	47	19	been	be	AUX
dpc-1032	47	20	proven	prove	VERB
dpc-1032	47	21	yet	yet	ADV
dpc-1032	47	22	in	in	ADP
dpc-1032	47	23	the	the	DET
dpc-1032	47	24	literature	literature	NOUN
dpc-1032	47	25	.	.	PUNCT
dpc-1032	48	1	references	reference	NOUN
dpc-1032	48	2	1	1	NUM
dpc-1032	48	3	.	.	PUNCT
dpc-1032	48	4	baroni	baroni	PROPN
dpc-1032	48	5	a	a	PROPN
dpc-1032	48	6	,	,	PUNCT
dpc-1032	48	7	piccolo	piccolo	NOUN
dpc-1032	48	8	v	v	NOUN
dpc-1032	48	9	,	,	PUNCT
dpc-1032	48	10	russo	russo	PROPN
dpc-1032	48	11	t	t	PROPN
dpc-1032	48	12	,	,	PUNCT
dpc-1032	48	13	cozzolino	cozzolino	PROPN
dpc-1032	48	14	d	d	PROPN
dpc-1032	48	15	,	,	PUNCT
dpc-1032	48	16	mascolo	mascolo	PROPN
dpc-1032	48	17	m	m	PROPN
dpc-1032	48	18	,	,	PUNCT
dpc-1032	48	19	chessa	chessa	PROPN
dpc-1032	48	20	ma	ma	PROPN
dpc-1032	48	21	.	.	PROPN
dpc-1032	48	22	norfloxacin	norfloxacin	PROPN
dpc-1032	48	23	-	-	PUNCT
dpc-1032	48	24	in6	in6	NOUN
dpc-1032	48	25	weeks	week	NOUN
dpc-1032	48	26	.	.	PUNCT
dpc-1032	49	1	the	the	DET
dpc-1032	49	2	patient	patient	NOUN
dpc-1032	49	3	improved	improve	VERB
dpc-1032	49	4	significantly	significantly	ADV
dpc-1032	49	5	after	after	ADP
dpc-1032	49	6	4	4	NUM
dpc-1032	49	7	weeks	week	NOUN
dpc-1032	49	8	and	and	CCONJ
dpc-1032	49	9	had	have	VERB
dpc-1032	49	10	a	a	DET
dpc-1032	49	11	complete	complete	ADJ
dpc-1032	49	12	remission	remission	NOUN
dpc-1032	49	13	in	in	ADP
dpc-1032	49	14	3	3	NUM
dpc-1032	49	15	months	month	NOUN
dpc-1032	49	16	(	(	PUNCT
dpc-1032	49	17	figure	figure	NOUN
dpc-1032	49	18	1	1	NUM
dpc-1032	49	19	,	,	PUNCT
dpc-1032	49	20	g	g	NOUN
dpc-1032	49	21	and	and	CCONJ
dpc-1032	49	22	h	h	NOUN
dpc-1032	49	23	)	)	PUNCT
dpc-1032	49	24	.	.	PUNCT
dpc-1032	50	1	successively	successively	ADV
dpc-1032	50	2	,	,	PUNCT
dpc-1032	50	3	to	to	PART
dpc-1032	50	4	reduce	reduce	VERB
dpc-1032	50	5	the	the	DET
dpc-1032	50	6	corticosteroid	corticosteroid	NOUN
dpc-1032	50	7	intake	intake	NOUN
dpc-1032	50	8	,	,	PUNCT
dpc-1032	50	9	in	in	ADP
dpc-1032	50	10	cooperation	cooperation	NOUN
dpc-1032	50	11	with	with	ADP
dpc-1032	50	12	his	his	PRON
dpc-1032	50	13	rheumatologist	rheumatologist	NOUN
dpc-1032	50	14	,	,	PUNCT
dpc-1032	50	15	an	an	DET
dpc-1032	50	16	off	off	ADP
dpc-1032	50	17	-	-	PUNCT
dpc-1032	50	18	label	label	NOUN
dpc-1032	50	19	treatment	treatment	NOUN
dpc-1032	50	20	with	with	ADP
dpc-1032	50	21	adalimumab	adalimumab	NOUN
dpc-1032	50	22	(	(	PUNCT
dpc-1032	50	23	40	40	NUM
dpc-1032	50	24	mg	mg	NOUN
dpc-1032	50	25	every	every	DET
dpc-1032	50	26	2	2	NUM
dpc-1032	50	27	weeks	week	NOUN
dpc-1032	50	28	subcutaneously	subcutaneously	ADV
dpc-1032	50	29	)	)	PUNCT
dpc-1032	50	30	was	be	AUX
dpc-1032	50	31	started	start	VERB
dpc-1032	50	32	.	.	PUNCT
dpc-1032	51	1	after	after	ADP
dpc-1032	51	2	a	a	DET
dpc-1032	51	3	3	3	NUM
dpc-1032	51	4	-	-	PUNCT
dpc-1032	51	5	month	month	NOUN
dpc-1032	51	6	follow	follow	NOUN
dpc-1032	51	7	-	-	PUNCT
dpc-1032	51	8	up	up	NOUN
dpc-1032	51	9	,	,	PUNCT
dpc-1032	51	10	no	no	DET
dpc-1032	51	11	relapse	relapse	NOUN
dpc-1032	51	12	was	be	AUX
dpc-1032	51	13	observed	observe	VERB
dpc-1032	51	14	.	.	PUNCT